Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis | Zendy

Iain B. McInnes | Zendy; J. Anderson | Zendy; Marina Magrey | Zendy; Joseph F. Merola | Zendy; Yi Liu | Zendy; Mitsumasa Kishimoto | Zendy; Sławomir Jeka | Zendy; César PachecoTena | Zendy; Xin Wang | Zendy; Liang Chen | Zendy; Patrick Zueger | Zendy; John Liu | Zendy; Aileen L. Pangan | Zendy; Frank Behrens | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

Author(s) -

Iain B. McInnes,

J. Anderson,

Marina Magrey,

Joseph F. Merola,

Yi Liu,

Mitsumasa Kishimoto,

Sławomir Jeka,

César PachecoTena,

Xin Wang,

Liang Chen,

Patrick Zueger,

John Liu,

Aileen L. Pangan,

Frank Behrens

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2022516

Subject(s) - adalimumab , psoriatic arthritis , medicine , janus kinase , pharmacology , arthritis , tumor necrosis factor alpha , dermatology , receptor

The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor α inhibitor, in patients who have an inadequate response to nonbiologic disease-modifying antirheumatic drugs are unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research